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Abstract
Background: The skin is the largest organ of the human body and is the first line barrier defence against trauma,
microbial infiltration and radiation. Skin diseases can be a result of multi-systemic disease or an isolated condition.
Due to its proteolysis resistant properties there are relatively few human skin proteomic datasets published
compared with other human organs or body fluids. Skin is a challenging tissue to analyse using traditional
proteomic techniques due to its high lipid content, insolubility and extensive cross-linking of proteins. This can
complicate the isolation and digestion of proteins for analysis using mass spectrometry techniques.
Results: We have optimised a sample preparation procedure to improve solubilisation and mass spectral
compatibility of full thickness skin samples. Using this technique, we were able to obtain data for the proteome
profile of full thickness human skin using on-line two-dimensional liquid chromatography, followed by ultra-high
definition label-free mass spectrometry analysis (UDMSE). We were able to identify in excess of 2000 proteins from a
full thickness skin sample.
Conclusions: The adoption of on-line fractionation and optimised acquisition protocols utilising ion mobility
separation (IMS) technology has significantly increased the scope for protein identifications ten-fold.
Keywords: Proteomics, Skin profiling, Mass spectrometry, Solubilisation
Background
The skin, being the largest organ of our bodies is of
paramount importance for barrier protection and first
line defence against trauma, microbial infiltration and
radiation. However when this barrier is damaged or dis-
eased numerous dermatological conditions can arise.
These diseases by their nature are superficial, visible and
can look unpleasant, which can contribute to a signifi-
cant psychological and social burden [1].
To understand more about diseases affecting the skin
and the skin barrier in particular, it is important that we
understand the complex composition of proteins, metab-
olites and lipids that make up the skin and how they
play a functional role in its overall structure. The skin
consists of three major distinct layers; the epidermis,
dermis and the subcutaneous fat layer. The purpose of
the subcutaneous fat layer is largely for insulation, the
dermis is predominantly made up of collagens, elastin
and fibrillin as well as nerve endings, sweat glands, se-
baceous glands, hair follicles and major blood vessels
providing nutrients for the epidermal layer [2]. The epi-
dermis is the most superficial layer of the skin and
comprises the skin barrier; despite being the thinnest of
all three layers it is arguably the most complex [3].
Despite the importance of the skin there are relatively
few human skin proteomic studies and datasets cur-
rently available in the literature [4] compared with other
human organs or body fluids. A human-specific PubMed
search shows that there are three times as many publica-
tions for “liver AND proteomics” [5] and twelve times as
many publications for “blood AND proteomics” [6] com-
pared with publications for “skin AND proteomics” [7].
Skin is a challenging tissue to analyse using traditional
proteomic techniques due to its high lipid content, in-
solubility and extensive cross-linking of proteins. This
can complicate the isolation and digestion of proteins
for analysis using mass spectrometry techniques. Tech-
niques used by research groups in the current selection of* Correspondence: emily.bliss.10@ucl.ac.uk
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available publications about skin proteomics [7] include
gel-based protein fractionation [8, 9], heavy isotope labelled
assays to identify phosphorylated proteins [10] and studying
the proteins secreted by the skin, rather than the skin tissue
itself [11]. The latter two techniques are specific to a par-
ticular aspect of the skin proteome and do not represent
the composition of the skin tissue as a whole. Gel-based
protein isolation or fractionation techniques is a viable
method for preparing samples prior to mass spectrometry
analysis and one which we explored whilst developing the
method presented in this paper. When comparing a gel-
based fractionation technique and the on-line fractionation
technique described here we found a 50 % increase in the
number of proteins detected (data not shown).
Here we describe an optimised method of fractionat-
ing, chromatographically separating and detecting pro-
teins from a trypsin digested sample of human skin.
This method is relatively quick, consists of less sample
preparation steps and less protein (3 μg) compared with
similar gel-based methods.
Results
Previously in our laboratory we have been able to iden-
tify 100–200 proteins from a full thickness skin biopsy
[12], however with an upgraded system and modified
methods we have improved this protocol and achieved a
ten-fold increase in the number of identified proteins. In
order to be a fair comparison the results presented in
this section are from the same sample of skin tissue and
are representative of the number of proteins detected by
these methods from other samples of skin (data not
shown). In the first instance the skin preparation
method comprised of powdering the frozen tissue using
a pestle and mortar, further homogenisation using a
glass homogeniser, sonication, filtration of interfering
low molecular weight compounds. This was a method
adapted from other published proteomics methods for
other tissues [13–15]. Peptides would then be separated
using reverse phase chromatography a nanoAcquity li-
quid chromatography system coupled to a quadrupole
time-of-flight mass spectrometer (QToF Premier, Waters,
Manchester) [12] (Fig. 1). Using this workflow 218 pro-
teins were identified from the skin samples as detailed in
Additional file 1: Table S1.
Modifying the initial preparation method (Fig. 2) im-
proved the number of detected proteins, to 2237 proteins,
from the same sample of skin, those proteins are detailed
in Additional file 2: Table S2.
Improved chromatographic separation was achieved
using on-line fractionation technology [16] integrated
with a nanoAcquity ultra-high performance liquid
Fig. 1 Diagram showing the generic workflow for preparing skin punch biopsies for MS analysis, including a low molecular weight species
clean-up step. Points 1–12 show the sample preparation procedure that was originally used
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chromatography (UPLC) system (Fig. 3) rather that
the shotgun approach of the initial method (Fig. 1).
One-dimensional (1D) separation is when the sample
is injected onto the trapping column then the analytical
column, the peptides are chromatographically separated
according to polarity by an increasing concentration of
acetonitrile over a 1 h gradient. Two-dimensional (2D)
separation reduces the complexity of the sample by
dividing it into multiple fractions, in this case eight on
an additional fractionation column. Those fractions
were then individually applied to the trapping column,
then analytical column for chromatographic separation
for the same 1 h acetonitrile gradient as the 1D sam-
ples and this was repeated for each individual fraction,
totalling 8 hs of chromatographic separation for the
2D samples.
Further improvement in peptide quantitation and
identification is achieved an optimised acquisition on a
quadrupole time-of-flight mass spectrometer to include
an additional ion mobility dimension of separation
(SYNAPT G2-Si, Waters, Manchester) and capabilities
of tailoring the collision energy ramp to the characteris-
tic signature of peptides from this matrix (UDMSE).
Discussion
In the first instance in our laboratory we analysed full
thickness skin samples using the standard laboratory
protocol, as shown in Fig. 1. That method allowed us
to identify 218 proteins (Additional file 2: Table S1).
We believed that this method could be altered to in-
crease coverage of the skin proteome (Figs. 2 and 3).
Two noticeably inefficient steps were the powdering
and homogenisation. This was time consuming, not
reproducible and inefficient (data not shown). Instead
we chose to slice the skin using a cryostat into 20 μm
sections and apply mechanical homogenisation using a
ceramic bead homogeniser. We found this method to
be quicker, more reproducible and efficient (data not
shown). Another modification is the removal of the fil-
tration step with a low molecular weight cut off filter.
Instead to remove the majority of salts and hydropho-
bic compound such as lipids we used reverse phase
carbon-18 (C18) pre-packed cartridges. C18 cartridges
were selected because this is the same chemistry used
in the solid phase of the on-line chromatographic sep-
aration thereby the samples are purified appropriately
for the system.
Fig. 2 Diagram showing the modified workflow for preparing skin punch biopsies for MS analysis. Points 1–7 show the modified sample
preparation procedure, which reduced sample preparation time and increased the depth of proteome coverage of the skin samples, compared
with the previous workflow (Fig. 1)
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Finally the liquid chromatography system was modi-
fied to include an additional binary solvent manager
which allows the samples to be fractionated on-line
using high pH/low pH fractionation (Fig. 3) [17, 18].
One-dimensional separation is quicker as it involved 1 h
or chromatographic separation, whereas 2D separation
reduced the complexity of the sample into eight separate
fractions for analysis, totalling 8 hs of chromatographic
separation and greater proteome coverage. The applica-
tion of IMS to the mass spectral analysis also greatly
improved this method. IMS in this case uses travelling-
waves of helium gas against the flow of ions in order to
separate co-eluting compounds based on shape and size
giving each ion an unique ‘drift time’ measure thereby
introducing an additional degree of separation of the
ions [19, 20].
Having introduced these changes we have been able to
identify 2237 proteins from a single skin sample (Additional
file 2: Table S2), ten-fold greater than previously achieved
in our group (Additional file 1: Table S1).
This method could equally be applied to other chal-
lenging or insoluble tissues such as formalin-fixed
paraffin-embedded archived samples. Having developed
this technique we will now be able to use the method
to further study the skin in health and disease. We
hope to be able to shed light on disease mechanisms
and underlying biochemical changes that increase sus-
ceptibility to certain skin diseases. Further functional
characterisation could also be achieved by physical sep-
aration of the skin layers. This is currently only achiev-
able using laser capture technology that uses a very fine
laser beam to cut out and collect sections of tissue
from a microscope slide.
Conclusions
In conclusion by modifying the sample preparation method,
using a more complex liquid chromatography setup (2D-
fractionation) and more recent mass spectrometry separ-
ation techniques (IMS) we have successfully been able to
modify our original protocol in order to increase ten-fold
the proteome coverage for skin samples.
Methods
Experiment design
We aimed to create a mass spectrometry-based method
and workflow that would allow us to use proteomics to
profile full thickness human skin. Using skin from surgi-
cally removed accessory digits, nanoflow UPLC online
fractionation and separation before label-free UDMSE
raw data acquisition we were able to profile over 2000
proteins.
Materials
All reagents and materials were purchased from Sigma-
Aldrich, Poole, UK, unless stated otherwise. All solvents
were of UPLC or higher grade specification.
Human skin sample collection
The skin sample was obtained from the surface of an
accessory digit surgically removed at Great Ormond
Street Hospital, London. The skin was separated from
the underlying tissue using a clean scalpel blade.
Solubilisation of tissue and determination of protein
concentration of the sample
Skin tissue was washed with a 1x phosphate buffer solution
before being snap frozen in liquid nitrogen, embedded in
Fig. 3 Figure detailing the original “1D” setup of the nanoAcquity and the upgraded “2D” setup including an additional module and column and
the capability of on-line fractionating. This figure shows how in the original nanoAcquity LC “1D” setup the sample would be injected into the
sampling loop, then be desalted on the trapping column, before being chromatographically separated on the analytical column. However in the
upgraded “2D” setup there is an additional column after the sampling loop from which the sample is eluted from in individual fractions
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optimum cutting temperature (Cell Path, Fisher Scientific),
cryosectioned into 10 μm rolled tissue sections (Leica
CM1860) and collected in a clean tube. The curls were sus-
pended in 500 μL of 50 mmol/L ammonium bicarbonate
containing 2 % w/v amidosulphobetanine-14. Curls and so-
lution were transferred to a homogenisation vial (Precellys
0.5 mL tube containing 1.4 mm diameter ceramic beads,
peqlab, VWR) and mechanically homogenised for 20 s at
high power (Minilys®, Bertin Technologies). The solution
was then transferred to ice for 1 min to stop thermal deg-
radation. This was repeated a further two times. The vial
was then incubated on ice for 1 h before a further three cy-
cles of homogenisation. The homogenate was transferred
to a clean tube and sonicated for 10 s using a Soniprep 150
sonicator (MSE UK). The sample was spun at 16,000 g for
10 min and the supernatant removed to a clean tube. A
modified Lowry (Pierce™, ThermoFisher Scientific) protein
assay was used to calculate the protein content of the
sample.
In-solution digestion of the homogenised sample
The equivalent of 50 μg of protein solution was taken
and lyophilised using a freeze-drier. The pellet was
reconstituted in 20 μL of 100 mmol/L trisma base,
pH 7.8, containing 2 % w/v amidosulphobetanine-14,
6 mol/L urea and 2 mol/L thoiurea. To this solution
1.5 μL of a 1.94 mol/L dithioerythritol solution made up
in 100 mmol/L trisma base, pH 7.8 was added, the sample
vortexed, centrifuged briefly and incubated on a platform
shaker at room temperature for 1 h. Three microlitres of a
1.94 mol/L2-iodoacetamide solution made up in 100 mol/L
trisma base, pH 7.8 was added, the sample vortexed,
centrifuged briefly and incubated at room temperature
on a platform shaker for 45 min. The reaction volume
was made up to 190 μL with Milli-Q water (Merck
Millipore, Merck KGaA, Germany). Ten microlitres of
0.1 mg/mL Sequencing Grade Modified Trypsin (Promega,
Madison, USA) was added, the sample vortexed briefly and
incubated overnight at 37 °C.
Purification of the digested sample peptides reverse
phase C-18 chromatography
In order to remove the salt and lipid content of the sam-
ple, 100 μL of the digest solution was taken for a clean-up
step using ISOLUTE® C18 columns (Biotage) was used.
Two dimensional high pH fractionation of sample
peptides, followed by low pH chromatographic
separation using an online nanoAcquity ultra high
performance liquid chromatography system
The lypholised sample was reconstituted in 25 μL of
3 % v/v acetonitrile containing 0.1 % v/v trifluoroacetic acid
and 50 pmol/μL enolase peptides standard (MassPREP™,
Waters) solution, centrifuged at 16,000 g for 10 mins and
the supernatant transferred to a vial (TruView™ LCMS Cer-
tified, Total Recovery Vial, Waters). The nanoACQUITY
UPLC (Waters, Manchester) system was configured in 2D
with dilution set-up to allow for the first dimension to
online fractionate the sample using high pH mobile
phases directly before individual fractions entered the
second dimension of chromatographic separation using
low pH mobile phases. The first dimension was performed
at 2 μL/min flow on an XBridge Peptide ethylene bridged
hybrid C18 NanoEase Column (130 Å, 5 μm, 300 μm X
50 mm, 1/pkg (PN: 186003682), Waters, Manchester) mo-
bile phase A was a 20 mmol/L ammonium formate, pH 9
solution and mobile phase B was 100 % acetonitrile. At
the beginning of the first dimension 2.4 μL of the sample
solution was loaded onto the XBridge Peptide column in
3 % mobile phase B for 1 min before a 4 min gradient up
to 8.7 %, 11.8 %, 13.6 %, 15.3 %, 17.1 %, 19.3 %, 22.5 % and
50 % mobile phase B respectively for the 8 sequential frac-
tions, after which the XBridge Peptide column was re-
equilibrated at 3 % mobile phase B. After a fraction has
been eluted from the XBridge Peptide column it enters
the second dimension constituting low pH reverse phase
chromatographic separation at 400 nL/min flow on an
ACQUITY UPLC Peptide ethylene bridged hybrid C18
nanoACQUITY Column (10 Kpsi, 130 Å, 1.7 μm, 75 μm
X 150 mm (PN: 186003543), Waters, Manchester) main-
tained at 35 °C, mobile phase A was 0.1 % v/v formic acid
with 5 % v/v dimethyl sulphoxide and mobile phase B was
0.1 % v/v formic acid in 100 % acetonitrile with 5 % v/v
dimethyl sulphoxide. Before the peptides from the first
dimension are chromatographically separated they were
diluted 1:10 during trapping with mobile phase A from
the second dimension (20 μL/min 0.1 % formic acid with
5 % v/v dimethyl sulphoxide), concentrated and further
desalted onto a nanoACQUITY UPLC Symmetry C18
Trap Column (100 Å, 5 μm, 180 μm x 20 mm, 2G, V/M
(PN:186006527), Waters, Manchester). The second di-
mension gradient starts 20.5 min after the start of the first
dimension at 3 % mobile phase B and increases to 40 %
over 40 min, a further increase to 85 % mobile phase B oc-
curs over the next 2 min and is held there for 2 min fur-
ther, before returning to the starting conditions for 15 min
of re-equilibration.
Label-free UDMSE mass spectrometry data acquisition
For each fraction a 60 min mass spectrometry analysis
was performed on a SYNAPT G2-Si (Waters, Manchester)
mass spectrometer in a UDMSE mode in positive ion elec-
trospray ionisation mode and operated in V-mode [21].
One second alternating high and low energy scans were
performed at a capillary voltage of 3.0 kV, sampling cone
voltage of 40 V, a source temperature of 70 °C over a mass
range of 50–2000 Da in resolution analyser mode. Prior to
fragmentation ion mobility separation was performed at a
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wave velocity of 650 m/s and a wave height of 40 V in
order to separate similar precursor ions. The low energy
scans were performed at a collision energy of 0 V and the
high energy scans were performed on a gradient designed
to use an optimised collision energy depending on the ion
mobility bin, from 0–20 ion mobility bins the collision en-
ergy was 13.6 V increasing linearly to 49.1 V at 120 mobil-
ity bins, followed by another linear gradient to 54.1 V at
200 mobility bins. At a frequency of every 60 s lock mass
of [glutamic acid1]-fibrinopeptide B is delivered via an
auxiliary pump at 300 nL/min.
Analysis and quantification of raw mass spectrometry files
Raw data were imported into Waters ProteinLynx Global-
Server version 3.0.1 in order to identify peptide masses
corresponding to the fragmentation ion data. Mass correc-
tions was applied based on the [glutamic acid1]-fibrino-
peptide B mass delivered via an auxiliary pump. The
processed spectra were merged prior to searching the
UniProt reviewed human proteome. Database searching
parameters were set to two fragment ions matched per
peptide, four fragment ions per protein and two pep-
tides per protein and one missed cleavage, fixed modifi-
cations were set to carbamidomethylation of cysteines
and dynamic modifications of hydroxylation of aspartic
acid, lysine, asparagine and proline and oxidation of
methionine and the false discovery rate set to 4 %.
Additional files
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